CD274 and non-small cell lung carcinoma: While some research posed that TP53 co-mutations were not related to survival outcomes, others suggested that TP53 co-mutations were related to survival benefits of KRASm NSCLC, especially in first-line immunotherapy.21,27,55,57 Additionally, Aredo et al. showed that TP53 co-mutations were more frequently found with high PD-L1 expression (≥50%).53 This association may explain the prolonged survival in KRASm patients with TP53 co-mutations receiving immunotherapy.